EP0866710A4 - Compositions et procedes pour le traitement des deficits osseux - Google Patents

Compositions et procedes pour le traitement des deficits osseux

Info

Publication number
EP0866710A4
EP0866710A4 EP96936906A EP96936906A EP0866710A4 EP 0866710 A4 EP0866710 A4 EP 0866710A4 EP 96936906 A EP96936906 A EP 96936906A EP 96936906 A EP96936906 A EP 96936906A EP 0866710 A4 EP0866710 A4 EP 0866710A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
treating bone
deficit conditions
bone deficit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96936906A
Other languages
German (de)
English (en)
Other versions
EP0866710A1 (fr
Inventor
Charles Petrie
Mark W Orme
Nand Baindur
Kirk G Robbins
Scott M Harris
Maria Kontoyianni
Laurence H Hurley
Sean M Kerwin
Gregory R Mundy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
OsteoScreen Inc
University of Texas at Austin
Original Assignee
Zymogenetics Inc
OsteoScreen Inc
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, OsteoScreen Inc, University of Texas at Austin filed Critical Zymogenetics Inc
Publication of EP0866710A1 publication Critical patent/EP0866710A1/fr
Publication of EP0866710A4 publication Critical patent/EP0866710A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP96936906A 1995-10-23 1996-10-23 Compositions et procedes pour le traitement des deficits osseux Withdrawn EP0866710A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US583095P 1995-10-23 1995-10-23
US5830P 1995-10-23
PCT/US1996/017019 WO1997015308A1 (fr) 1995-10-23 1996-10-23 Compositions et procedes pour le traitement des deficits osseux

Publications (2)

Publication Number Publication Date
EP0866710A1 EP0866710A1 (fr) 1998-09-30
EP0866710A4 true EP0866710A4 (fr) 2001-07-11

Family

ID=21717974

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96936906A Withdrawn EP0866710A4 (fr) 1995-10-23 1996-10-23 Compositions et procedes pour le traitement des deficits osseux

Country Status (13)

Country Link
EP (1) EP0866710A4 (fr)
JP (1) JP2000513324A (fr)
KR (1) KR19990067010A (fr)
CN (1) CN1201393A (fr)
AU (1) AU706262B2 (fr)
BR (1) BR9611210A (fr)
CA (1) CA2235481A1 (fr)
CZ (1) CZ115398A3 (fr)
EA (1) EA199800393A1 (fr)
HU (1) HUP9802319A3 (fr)
NO (1) NO981810L (fr)
PL (1) PL327617A1 (fr)
WO (1) WO1997015308A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9711805A (pt) * 1996-06-20 2002-01-15 Regents The Univesity Of Texas Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos
JP2001510450A (ja) * 1996-10-23 2001-07-31 ザイモジェネティクス，インコーポレイテッド 骨欠損状態を処置するための組成物および方法
US6376476B1 (en) 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
US6080779A (en) * 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
WO1999009986A1 (fr) * 1997-08-22 1999-03-04 Kyowa Hakko Kogyo Co., Ltd. Derives de 4-aminoquinazoline
US6649631B1 (en) 1997-10-23 2003-11-18 The Board Of Regents Of The University Of Texas System Compositions and methods for treating bone deficit conditions
DE19812204A1 (de) * 1998-03-19 1999-11-04 Plantamed Arzneimittel Gmbh Verwendung von Extrakten aus Cimicifuga racemosa und Belamcanda sinensis als estrogenartiges organselektives Arzneimittel ohne uterotrope Wirkung
JP2000004882A (ja) * 1998-06-18 2000-01-11 Hoechst Marion Roussel Kk ヒトｍｐ５２遺伝子プロモーターおよびこれを用いた有用物質の探索法
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
KR20010086005A (ko) * 1998-11-06 2001-09-07 스타르크, 카르크 트리사이클릭 피라졸 유도체
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
AU5250400A (en) * 1999-06-18 2001-01-09 Mitsubishi Pharma Corporation Osteogenesis promoters
WO2001017562A1 (fr) * 1999-09-02 2001-03-15 Yamanouchi Pharmaceutical Co., Ltd. Agents promoteurs de l'osteogenese
HUP0203973A3 (en) 1999-12-28 2004-07-28 Eisai Co Ltd Heterocyclic compounds having sulfonamide groups, pharmaceutical compositions containing them and their use
FR2806408B1 (fr) * 2000-03-17 2002-10-11 Oreal Composition cosmetique comprenant un derive de furane- naphtoquinone, leur utilisation comme agent colorant et derives
AU2001265656A1 (en) 2000-06-05 2001-12-17 Johnny Easmon Heterocyclic hydrazones for use as anti-cancer agents
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
WO2003082808A1 (fr) * 2002-04-03 2003-10-09 Sumitomo Pharmaceuticals Company, Limited. Derives de benzamide
CA2496633A1 (fr) * 2002-08-30 2004-04-29 Bf Research Institute, Inc. Sondes de diagnostic et remedes contre des maladies presentant une accumulation de la proteine du prion et methode de marquage
US7118730B2 (en) 2002-12-16 2006-10-10 Bf Research Institute, Inc. Quinoline derivative as diagnostic probe for disease with tau protein accumulation
AU2004209456A1 (en) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Quinoline-derived amide modulators of vanilloid VR1 receptor
EP1740551B9 (fr) 2004-04-30 2013-01-16 Takeda Pharmaceutical Company Limited Composé amide heterocyclique et utilisation de celui-ci en tant qu'inhibiteur mmp-13
JP2008530229A (ja) 2005-02-17 2008-08-07 ワイス シクロアルキル縮合インドール、ベンゾチオフェン、ベンゾフランおよびインデン誘導体
PL2118074T3 (pl) 2007-02-01 2014-06-30 Resverlogix Corp Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
WO2009076792A1 (fr) 2007-12-19 2009-06-25 Givaudan Sa Composés rafraîchissants
NZ586440A (en) 2008-06-26 2011-07-29 Resverlogix Corp Methods of preparing quinazolinone derivatives
ES2463097T3 (es) 2009-01-08 2014-05-27 Resverlogix Corp. Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
US20110319416A1 (en) * 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
NZ596117A (en) 2009-04-22 2014-10-31 Resverlogix Corp Novel anti-inflammatory agents
HUE044986T2 (hu) 2011-11-01 2019-11-28 Resverlogix Corp Orális, azonnali felszabadulású készítmények szubsztituált kinazolinonokhoz
EP3147280B1 (fr) 2012-07-18 2018-03-07 University College Dublin, National University of Ireland, Dublin Composé anti-angiogène
CN102942515A (zh) * 2012-10-22 2013-02-27 暨南大学 一种乙烯桥连吲哚化合物及其合成方法和用途
WO2014080290A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Amines cycliques servant d'inhibiteurs de bromodomaines
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
KR20150096794A (ko) 2012-12-21 2015-08-25 제니쓰 에피제네틱스 코포레이션 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
CN107019687B (zh) * 2017-05-08 2020-10-27 上海市伤骨科研究所 N-(4-氯苯基)-3-羟基-2-萘甲酰胺类化合物的用途
CN111116552B (zh) * 2020-01-17 2022-10-11 河北科技大学 一种喹唑啉酮类化合物及其制备方法
CN114469863B (zh) * 2021-11-26 2023-09-26 南方医科大学南方医院 甾醇脂质体作为牙髓和牙本质药物传递系统的应用
CN114288292B (zh) * 2021-12-10 2023-06-13 中南大学湘雅医院 芳香族化合物作为神经丛素蛋白-b2的激活剂以及在制备治疗骨质疏松症药物中的应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268990A2 (fr) * 1986-11-21 1988-06-01 Fujisawa Pharmaceutical Co., Ltd. Dérivés de benzothiadiazine, leurs procédés de préparation et compositions pharmaceutiques les contenant
JPH01238529A (ja) * 1987-12-18 1989-09-22 Takeda Chem Ind Ltd 骨粗鬆症予防治療剤
WO1992000071A1 (fr) * 1989-02-10 1992-01-09 Washington Research Foundation Agents immunoregulateurs
JPH06192272A (ja) * 1992-12-24 1994-07-12 Japan Tobacco Inc 新規なトリアゾロベンゾチアジアジン及びトリアゾロベンゾチアジアゼピン誘導体
WO1994020098A1 (fr) * 1993-03-11 1994-09-15 Zymogenetics, Inc. Procedes d'inhibition des pertes osseuses par le 3,4-diarylchromanne
EP0716086A1 (fr) * 1994-12-09 1996-06-12 Boehringer Mannheim Gmbh Inhibiteurs de métalloprotéinases matricielles à base d'acide malonique
WO1998017267A1 (fr) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions et methodes pour traiter les etats associes a un deficit osseux
WO1998025460A1 (fr) * 1996-12-13 1998-06-18 Zymogenetics, Inc. Compositions visant a stimuler la croissance osseuse et methodes afferentes

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268990A2 (fr) * 1986-11-21 1988-06-01 Fujisawa Pharmaceutical Co., Ltd. Dérivés de benzothiadiazine, leurs procédés de préparation et compositions pharmaceutiques les contenant
JPH01238529A (ja) * 1987-12-18 1989-09-22 Takeda Chem Ind Ltd 骨粗鬆症予防治療剤
WO1992000071A1 (fr) * 1989-02-10 1992-01-09 Washington Research Foundation Agents immunoregulateurs
JPH06192272A (ja) * 1992-12-24 1994-07-12 Japan Tobacco Inc 新規なトリアゾロベンゾチアジアジン及びトリアゾロベンゾチアジアゼピン誘導体
WO1994020098A1 (fr) * 1993-03-11 1994-09-15 Zymogenetics, Inc. Procedes d'inhibition des pertes osseuses par le 3,4-diarylchromanne
EP0716086A1 (fr) * 1994-12-09 1996-06-12 Boehringer Mannheim Gmbh Inhibiteurs de métalloprotéinases matricielles à base d'acide malonique
WO1998017267A1 (fr) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions et methodes pour traiter les etats associes a un deficit osseux
WO1998025460A1 (fr) * 1996-12-13 1998-06-18 Zymogenetics, Inc. Compositions visant a stimuler la croissance osseuse et methodes afferentes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 8944, Derwent World Patents Index; AN 1989-320493, XP002150794 *
DATABASE WPI Week 9432, Derwent World Patents Index; AN 1994-260503, XP002150793 *
IRVING, H.M.N.H. ET AL: "Studies with dithizone Part XXV. The deterioration of stock solutions and the identification of two oxidation products", ANALYTICA CHIMICA ACTA, vol. 56, no. 2, 1971, pages 205 - 220, XP000955697 *
MCDONALD, W.S. ET AL: "Relative reactivity of co-ordinated ligands in the dienyltricarbonyl-ruthenium cation, ((dienyl)Ru(CO)3)+", JOURNAL OFTHE CHEMICAL SOCIETY, no. 8, 1969, pages 392 - 393, XP000938351 *
See also references of WO9715308A1 *

Also Published As

Publication number Publication date
KR19990067010A (ko) 1999-08-16
CN1201393A (zh) 1998-12-09
AU706262B2 (en) 1999-06-10
PL327617A1 (en) 1998-12-21
NO981810L (no) 1998-06-22
CZ115398A3 (cs) 1998-12-16
HUP9802319A2 (hu) 1999-02-01
EP0866710A1 (fr) 1998-09-30
AU7471096A (en) 1997-05-15
NO981810D0 (no) 1998-04-22
EA199800393A1 (ru) 1998-12-24
JP2000513324A (ja) 2000-10-10
HUP9802319A3 (en) 1999-12-28
BR9611210A (pt) 1999-12-28
CA2235481A1 (fr) 1997-05-01
WO1997015308A1 (fr) 1997-05-01

Similar Documents

Publication Publication Date Title
EP0866710A4 (fr) Compositions et procedes pour le traitement des deficits osseux
EP0973513A4 (fr) Compositions et methodes pour traiter les etats associes a un deficit osseux
ZA963844B (en) Seed treatment composition and method
AU5439996A (en) Compositions and methods for treating pain
EP0874828A4 (fr) Compositions de traitement de la douleur
ZA965088B (en) Methods of preventing or treating allergles
IL134205A0 (en) Phototherapy based method for treating pathogens and compositions for effecting same
AP9300598A0 (en) Compositions and method for waste treatment
ZA963185B (en) Method and compositions for treating impotence
GB9506926D0 (en) Cystine-siicone copolymers and their use for treating keratin substrates
IL118196A0 (en) Methods for inhibiting bone loss
EP0784464A4 (fr) Composition et procede de traitement capillaire
IL129555A0 (en) Methods and compositions for stimulating neurite growth
EP0824316A4 (fr) Compositions et procedes permettant de stimuler la croissance de poils
GB9520615D0 (en) Method of preventing bone loss
EP1109548A4 (fr) Utilisation de procedes et de compositions a base de tocotrienols pour traiter et prevenir les maladies osseuses
GB9621570D0 (en) Formulations and methods for inhibiting bone loss
IL115021A0 (en) Methods for inhibiting bone prosthesis degeneration
IL111554A0 (en) Methods and compositions for hair treatment
AU5594398A (en) Methods and compositions for preventing and treating bone loss
EP0835092A4 (fr) Composition et traitement pour la lutte contre la calvitie
ZA962636B (en) Compositions and process for treating hemangioma
AU5791698A (en) Methods and compositions for preventing and treating bone loss
IL124419A0 (en) Composition for treating pain
PL326924A1 (en) Compositions for and methods of preventing and treating mouth mucositis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980511

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KERWIN, SEAN, M.

Inventor name: HURLEY, LAURENCE, H.

Inventor name: KONTOYIANNI, MARIA

Inventor name: HARRIS, SCOTT, M.

Inventor name: ROBBINS, KIRK, G.

Inventor name: BAINDUR, NAND

Inventor name: ORME, MARK, W.

Inventor name: PETRIE, CHARLES

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/54 A, 7A 61K 31/35 B

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/54 A, 7A 61K 31/35 B, 7A 61P 19/00 B, 7A 61K 45/06 B

A4 Supplementary search report drawn up and despatched

Effective date: 20010522

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020425

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050520